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Abstract 
Introduction 
Social anxiety disorder (SAD) is among the most prevalent mental disorders, associated 
with impaired functioning and poor quality of life. Pharmacotherapy is the most widely utilized 
treatment option. The current study provides an updated meta-analytic review of the efficacy of 
pharmacotherapy and examines moderators and mediators of treatment efficacy. 
Areas Covered 
 A comprehensive search of the current literature yielded 52 randomized, pill placebo-
controlled trials of pharmacotherapy for adults diagnosed with SAD. Data on potential mediators 
of treatment outcome were collected, as well as data necessary to calculate pooled correlation 
matrices to compute indirect effects.  
Expert Opinion 
 The overall effect size of pharmacotherapy for SAD is small to medium (Hedges’ g = 
0.41). Effect sizes were not moderated by age, sex, length of treatment, initial severity, risk of 
study bias, or publication year. Furthermore, reductions in symptoms mediated 
pharmacotherapy’s effect on quality of life. Support was found for reverse mediation. Future 
directions may include sustained efforts to examine treatment mechanisms of pharmacotherapy 
using rigorous longitudinal methodology to better establish temporal precedence. 
 
 
 
 
1. Introduction 
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 Social anxiety disorder (SAD) is among the most ubiquitous emotional disorders with a 
lifetime prevalence of 12.1% [1]. Individuals with SAD often experience an unremitting course 
associated with numerous functional impairments and diminished quality of life [1-4]. Although 
cognitive behavior therapy (CBT) is regarded as one of the most efficacious treatments for SAD 
[5-6], pharmacological interventions are more prevalent and widely utilized. Of the various 
pharmacological interventions that have been applied to SAD, most published randomized 
controlled trials have examined the efficacy of antidepressants (e.g., selective serotonin reuptake 
inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs)), monoamine 
oxidase inhibitors (MAOIs), and benzodiazepines. Despite the fact that prior research has 
substantiated the efficacy of these pharmacological treatments, relatively little is known about 
the potential mechanisms underlying pharmacotherapy [7].  
Indeed, a number of individual treatment mechanisms have been investigated in CBT, 
such as changes in estimated social cost and extinction learning [8-9]. Extant literature suggests 
that antidepressants and MAOIs are associated with improvement in more general mental health 
domains such as quality of life (QOL) [10-11]. As regards pharmacotherapy, it may be the case 
that it exerts its therapeutic effect on QOL by way of reducing symptoms of social anxiety. 
Because individuals with SAD experience impaired QOL, treatments that enhance overall QOL 
may do so through remission of social anxiety symptoms [12]. 
Thus, the principle objective of the current meta-analysis is to review and analyze extant 
randomized, placebo controlled trials of pharmacotherapy for SAD to: 1) provide an updated 
controlled effect-size of pharmacotherapy for symptoms of anxiety; 2) examine potential 
moderators of treatment efficacy; and 3) investigate the mediation hypothesis that 
pharmacotherapy confers its indirect effect on QOL by way of symptom reduction. 
	 	 Pharmacotherapy	for	SAD	 4	
2. Method 
2.1 Search Strategy 
 A comprehensive search was conducted in the PsycINFO (1840 to May 2016), 
MEDLINE (1966 to October 2016), and Scopus (1869 to October 2016) databases for 
randomized placebo-controlled pharmacotherapy trials for SAD. The following search terms 
were used to search key words, title, abstract, and Medical Subject Headings: 
“pharmacotherapy”, “medication”, or “pharmacology”; “social anxiety”, “social anxiety 
disorder”, “SAD”, or “social phobia”; and “trial”, or “clinical trial”. Furthermore, we also 
examined citation maps and used “cited by” search strategies to locate studies which were then 
cross-referenced with references from reviews.  
2.2 Inclusion/Exclusion Criteria 
For the current meta-analysis, study eligibility was determined by the following inclusion 
criteria: (a) adult participants meeting diagnostic criteria for SAD; (b) pharmacotherapy for SAD 
including more than two doses (i.e., administrations) of medication; (c) a pill placebo control 
condition; (d) inclusion of specific measures of SAD treatment outcome, including: the 
Liebowitz Social Anxiety Scale (LSAS) total score, the Clinical Global Impression of Severity 
Scale (CGI-S), the Clinical Global Impression – Social Phobia Scale (CGI-SP), the Clinical 
Impression of Severity – Social Phobia Scale (CIS-SP), or the Social Phobia Disorders Severity 
and Change Form (SPDSC). Exclusion criteria included: (a) studies lacking sufficient data to 
conduct analyses; (b) treatment studies using only medication responders after a medication trial 
period; (c) single case studies; and (d) treatment conditions based on augmentation or studies 
aimed at treating comorbid diagnoses. 
2.3 Data Collection and Synthesis 
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 We collected data on pharmacotherapy class, number of participants, length of 
pharmacotherapy (in weeks), mean age, percentage of male/female participants, and initial 
severity. Study bias was assessed with the Cochrane risk of bias instrument. This tool involves 
assessing each study as containing a high, low or unclear level of bias risk in a number of 
domains using pre-specified criteria. The domains used in our assessment were: 1) Sequence 
Generation, which assesses whether allocation of participants to treatment condition are 
adequately generated in a random manner; 2) Allocation Concealment, which assesses whether 
treatment assignment was adequately concealed from investigators and participants prior to 
randomization; 3) Incomplete Outcome Data, which assesses whether outcome data are missing 
at random and imputed using appropriate methods; and 4) Selective Outcome Reporting, which 
determines whether pre-specified outcome variables of interest are adequately and completely 
reported. Following recommendations from the Cochrane guidelines, a total bias assessment was 
created for each study such that an ‘unclear’ rating in any category meant an ‘unclear risk’ 
overall rating unless there was a ‘high’ rating in any category, which lead to a ‘high risk’ overall 
rating. ‘Low risk’ studies had to be rated as ‘low’ in all four categories.  
 We estimated controlled effect sizes using Hedges’ g, which corrects for parameter bias 
due to small sample size [13]. To compute Hedges’ g, we extracted means and standard 
deviations, as well as information from significance tests (e.g., t, F) [13]. The pooled effect sizes 
were estimated using random effects models, which assume significant heterogeneity of the 
included studies. All standard analyses were completed with Comprehensive Meta-Analysis [14]. 
 To ascertain whether symptom remission mediated improvement in QOL, meta-analytic 
structural equation modelling was employed to estimate the indirect effect. In this model, we 
determined whether the effect of treatment condition (i.e., a dummy-coded variable denoting 
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treatment versus pill placebo) on QOL was mediated by symptom reduction. In accordance with 
established precedent, a two-stage structural equation modelling (TS-SEM) analysis was 
conducted by: (i) synthesizing correlation matrices between the X, M, and Y variables; and (ii) 
specifying a structural model on the pooled correlation matrix [14]. If a study did not explicitly 
report correlation matrices, then means, standard deviations, t-statistics, F-statistics, and effect 
sizes were extracted to compute correlation coefficients [16-17]. We also pursued a reverse 
mediation model in which QOL mediates the relationship between treatment condition and 
symptom reduction. The TS-SEM model was estimated in R with the metaSEM package.  
3. Results 
3.1 Study Characteristics 
 Our initial search yielded 2,202 abstracts (see Figure 1), of which 113 were deemed 
relevant to the current study after review and evaluated for inclusion and exclusion criteria. Of 
these, 67 did not meet inclusion criteria. Six studies were also identified from recently published 
meta-analyses [6]. The remaining 52 studies included pill placebo controlled comparisons to 
selective serotonin reuptake inhibitors (SSRIs; 22 studies), monoamine oxidase inhibitors 
(MAOIs; 7 studies), monoamine oxidase A inhibitors (MAO-As; 6 studies), serotonin-
norepinephrine reuptake inhibitors (SNRIs; 3 studies), anticonvulsants (4 studies), antipsychotics 
(1 study), benzodiazepines (2 studies), herbal supplements (1 study), and noradrenergic and 
specific serotonin antidepressants (NaSSAs; 1 study). Additionally, seven studies included 
multiple pill placebo controlled medication comparisons, including two studies comparing an 
SNRI and an SSRI, one study comparing two types of SSRIs, one study comparing two types of 
MAOIs, one study comparing an SSRI and an NK1 receptor agonist, one study comparing an 
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SSRI and an anticonvulsant, and one study comparing an MAOI and a beta blocker. These 52 
studies with a total sample size of 12,153 individuals are depicted in Table 1. 
3.2 Overall Efficacy of Pharmacotherapy 
 Controlled effect sizes, confidence intervals, and significance values for each study are 
presented in Table 2. The random effects meta-analysis yielded an overall, controlled effect size 
of Hedges’ g = 0.41 (95% CI: 0.36-0.46, z = 16.34, p < .001), which suggests that 
pharmacotherapy contributed to greater symptom remission than pill placebo. The fail-safe N 
analysis was conducted to address the file drawer problem [18, 19]. If the number of studies 
needed to reduce the effect size to a non-significant level (i.e., the fail-safe N) exceeds 5K+10, 
the effect is considered robust [13]. Results of the fail-safe N analysis were robust, suggesting 
that it would require 7,761 future or unpublished studies with an effect size of zero to attenuate 
the overall effect size to non-significance. Inspection of the funnel plot reveals effect sizes 
distributed roughly symmetrically around the mean effect size (see Figure 2). Using the Trim and 
Fill method [20], we determined that 9 studies would need to fall to the left of the mean (i.e., 
have an effect size smaller than the mean) and 0 studies would need to fall to the right of the 
mean (i.e., have an effect size larger than the mean) to make the plot symmetrical. The random-
effects model for the new imputed mean effect size revealed a Hedges’ g = 0.35 (95% CI: 0.28-
0.42).  
3.3 Moderator Analyses 
 A number of moderator analyses were conducted to determine whether treatment efficacy 
varies as a consequence of patient and study characteristics. A multiple meta-regression was 
computed with mean age, overall percentage of female participants, treatment duration, 
publication date, and initial severity as predictors. There was no significant relation between 
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effect size and age (β = -0.03, p = 0.17), overall percentage of female participants (β = 0.01, p = 
0.13), treatment duration (β = -0.01, p = 0.15), initial severity (β = -0.22, p = 0.06), or 
publication year (β = 0.01, p = 0.48). No significant differences were revealed between high 
(Hedges’ g = 0.39; 95% CI: 0.33-0.46, p < .001), low (Hedges’ g = 0.66; 95% CI: 0.29-1.05, p < 
.001), and unclear (Hedges’ g = 0.42; 95% CI: 0.28-0.55, p < .001) risks of study bias (QB = 
1.92, df = 2, p = 0.38). The overall class of pharmacotherapy did not moderate treatment efficacy 
(QB = 17.25, df = 10, p = 0.07). Furthermore, no significant differences were revealed between 
acute (Hedges’ g = 0.41; 95% CI: 0.36-0.46, p < .001) and long-term (Hedges’ g = 0.35; 95% 
CI: 0.04-0.68, p < 0.05) effects of pharmacotherapy (QB = 0.09, df = 1, p = 0.76).  
3.4 Mediator Analyses 
 Of all the studies included in the current meta-analysis, three studies included a 
psychometrically validated QOL measure (i.e., the Quality of Life Enjoyment and Satisfaction 
Questionnaire (QLESQ) and the Short Form Health Survey (SF-36)) [21-23]. Results of the 
traditional random effects meta-analysis demonstrated that the controlled effect size for QOL 
was Hedges’ g = 0.28 (95% CI: 0.13-0.44, z = 3.52, p < .001), which suggests that 
pharmacotherapy contributed to greater improvements in QOL than pill placebo. Furthermore, 
correlation matrices were synthesized from these three studies, and a structural equation model 
was specified such that treatment condition exerted an indirect effect on QOL through reductions 
in symptoms. Results of the TS-SEM analysis established that the indirect effect was significant 
(Standardized β = 0.14; 95% CI: 0.09-0.19), as well as the direct effect (Standardized β = 0.19; 
95% CI: 0.13-0.27), which indicates partial mediation. However, results of the reverse mediation 
model indicated that the indirect effect was significant (Standardized β = 0.10; 95% CI: 0.07-
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0.13), as well as the direct effect (Standardized β = 0.09; 95% CI: 0.06-0.13), suggesting partial 
mediation.  
4. Discussion 
 The current meta-analysis of 52 randomized, pill placebo controlled trials of 
pharmacotherapy for individuals diagnosed with SAD yielded an overall controlled effect size of 
Hedges’s g = 0.41, which reflects a small to medium effect of pharmacotherapy for SAD. The 
Fail-Safe N suggested that this effect size is robust, as 7,761 studies demonstrating null-effects 
would be required to attenuate the overall effect size to non-significance. Indeed, inspection of 
the funnel plot does not reveal substantial publication bias. Thus, the results of the current meta-
analysis substantiate pharmacotherapy as an efficacious intervention for SAD. 
To further understand the conditions under which pharmacotherapy is maximally 
efficacious, a number of treatment moderators were investigated. Consistent with a prior meta-
analysis [7], the moderator analyses provided no evidence that the efficacy of pharmacotherapy 
varies as a function of treatment duration, initial symptom severity, age, sex, and year of study 
publication. No differences in effect sizes were observed between different classes of study bias 
(i.e., low, high, and uncertain). Furthermore, it was also revealed that there were no significant 
differences between acute and long-term effects of pharmacotherapy.   
In an effort to elucidate potential treatment mechanisms underlying pharmacotherapy, 
meta-analytic structural equation modelling was employed to assess our mediation hypothesis. 
Consistent with our prediction, reductions in anxiety mediated pharmacotherapy’s effect on 
improvement in QOL. However, results of the reverse mediation were also significant, which 
prohibits definitive conclusions regarding temporal precedence of the mediator. Although prior 
research has examined neurobiological mechanisms targeted by pharmacotherapy (e.g., serotonin 
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receptors in the case of SSRIs) [24], there has been a relative dearth of research investigating 
psychological mechanisms underlying pharmacological interventions. A large literature on CBT 
suggests that this intervention ameliorates symptoms through a variety of treatment mechanisms 
(e.g., extinction learning, changes in cognitions, etc.) [8]. Despite the limited research on 
psychological mechanisms underlying pharmacotherapy, results of the current study indicate that 
it might confer its benefit on QOL by way of reductions in anxiety symptoms.  
 Certain limitations warrant mention. Relatively few studies examined head-to-head 
comparisons between different classes of active pharmacological interventions, precluding 
conclusions about whether a particular class of pharmacotherapy substantially outperforms 
another one. Because only three studies examined the effect of pharmacotherapy on QOL in 
SAD, it remains uncertain as to whether pharmacotherapy leads to substantial improvement in 
QOL. Furthermore, the results of the mediation analysis were derived from pre- to post-treatment 
changes in anxiety symptoms and in QOL, which do not yield the most robust test of mediation. 
Future studies should better establish temporal precedence of the mediator by including more 
frequent assessment points to ascertain whether decreases in symptoms actually precede 
increases in QOL. That notwithstanding, the current meta-analysis represents a crucial first effort 
in determining whether changes in social anxiety mediates the efficacy of pharmacotherapy on 
QOL. Another important limitation concerns the significant indirect effect of the reverse 
mediation analysis, which prohibits firm conclusions about the directionality of mediation. Thus, 
it may be the case that reductions in anxiety symptoms account for improvements in QOL and 
vice versa. To further enhance our understanding of pharmacotherapy for SAD, future research 
should employ more rigorous experimental designs to better delineate the psychological 
mechanisms underlying pharmacological interventions. For instance, a randomized controlled 
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trial in which both the outcome and mediator measures are assessed frequently (e.g., weekly) 
could enable richer conclusions as to whether changes in the mediator temporally precede 
changes in the outcome variable. 
5. Conclusion 
 In summary, results of this meta-analysis indicate that pharmacotherapy produces greater 
reduction in social anxiety symptoms relative to pill placebo. Evidence of efficacy was revealed 
for several classes of pharmacotherapy (e.g., SSRIs, SNRIs, MAOIs, etc.). Results also 
suggested that pharmacotherapy may also enhance QOL. Although the mediation analyses 
provided evidence that pharmacotherapy produces better QOL through symptom reduction, 
results of the reverse mediation analysis preclude definitive interpretations regarding 
directionality. 
6. Expert Opinion 
Although pharmacotherapy was associated with small to medium controlled effect sizes 
relative to pill placebo, this suggests that there is still considerable room for improvement above 
and beyond potential placebo effects. Results of the current meta-analysis are in accord with 
prior meta-analytic research that examined the efficacy of pharmacotherapy for SAD [6]. The 
largest number of studies supporting the efficacy of any given class of pharmacotherapy was 
found for SSRIs (Hedge’s g = 0.44) and MAOIs (Hedge’s g = 0.36). Consistent with prior 
research [6], available evidence indicates that SSRIs and MAOIs are the most reliably 
efficacious forms of pharmacotherapy for SAD.  The current meta-analysis, however, enables us 
to better appreciate the underlying mechanisms that may be responsible for the efficacy of 
pharmacotherapy. Even though symptom reduction and improvement in QOL were corroborated 
as possible treatment mechanisms in the current meta-analysis, it is still possible that 
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pharmacotherapy exerts its effect through other mechanisms. Because the studies included in the 
meta-analysis reported relatively few outcome variables, as almost none of them tested 
mediation hypotheses, it was only possible to examine a limited subset of mediators. Better 
understanding of the psychological mechanisms underlying pharmacotherapy is of great 
importance.  
That notwithstanding, results of the current meta-analysis accord well with prior literature 
suggesting that this treatment enhances QOL in individuals diagnosed with a variety of 
emotional disorders [25-26], which tend to be very comorbid [27-28]. This might suggest that 
pharmacological interventions such as SSRIs have broad spectrum effects that contribute to 
symptom remission across several conditions. Indeed, research attests to a strong inverse 
relationship between quality of life and anxiety symptoms [26], as the presence of a disease 
symptom (e.g., fear about speaking up at a meeting) can be often associated with the absence of 
some aspect of quality of life (e.g., employment satisfaction). Therefore, it would make 
conceptual sense that treatment response to pharmacotherapy results from mutually reinforcing 
improvements in both anxiety symptoms and quality of life.  
Another important consideration is that pharmacotherapy constitutes a heterogeneous 
class of interventions. The pharmacological interventions investigated in the current meta-
analysis are intrinsically anxiolytic, ameliorating symptoms of anxiety directly. Another class of 
pharmacotherapy is cognitive enhancers [29]. Rather than conferring anxiolytic effects by 
themselves, cognitive enhancers, such as d-cycloserine, facilitate learning processes. When used 
in combination with CBT, cognitive enhancers may enhance extinction learning that occurs 
throughout the context of exposure exercises, thereby augmenting CBT specific mechanisms 
[30-33]. In particular, d-cycloserine is characterized by well-defined psychological (i.e., 
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extinction learning) and neurobiological mechanisms (i.e., partial agonist of NMDA receptors). 
Consequently, these novel combination approaches may better enable researchers to develop 
maximally efficacious treatments. As our cumulative knowledge of treatment mechanisms 
increases, we will enrich our understanding of these interventions and optimize their 
implementation.  
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Table 1. Studies included in the meta-analysis             Risk of Bias 
Study Pharmacotherapy 
Type 
N Mean 
Age 
% 
Female 
Tx 
Weeks 
Outcome 
Measure 
Diagnostic 
Subtype 
S 
G 
A 
C 
I 
D 
S 
R 
total 
Allgulander et al., 1999 [34] paroxetine 92 41.0 NR 12 LSAS Mixed ✓ ? X ✓ X 
Allgulander et al., 2004 [35] paroxetine; 
venlafaxine ER 
389 38.8 53.4 12 LSAS GSAD ✓ 
 
✓ X ✓ X 
Asakura et al., 2007 [36] fluvoxamine 265 32.4 38.8 10 LSAS GSAD ? ? ✓ ✓ ? 
Baldwin et al., 1999 [37] paroxetine 290 36.1 54.2 12 LSAS; CGI-S Mixed ? ✓ X ✓ X 
Barnett et al., 2002 [38] olanzapine 12 NR NR 8 LSAS Mixed ? ? ✓ ✓ ? 
Blanco et al., 2010 [39] phenelzine 96 31.4 40.6 12 LSAS; CGI-S Mixed ✓ ✓ ✓ ✓ ✓ 
Blomhoff et al., 2001 [40] sertraline 277 40.4 60.5 24 CGI-SP GSAD ✓ ✓ ? ✓ ? 
Clark et al., 2003 [41] fluoxetine 60 33.2 52.0 16 LSAS GSAD ? ✓ ✓ ✓ ? 
Davidson et al., 1993 [42]* clonazepam 75 37.2 42.7 10 LSAS; CGI-S Mixed ? ? X ✓ X 
Davidson et al., 2004a [43]  fluoxetine 117 36.6 47.4 14 CGI-S GSAD ✓ ✓ ? ✓ ? 
Davidson et al., 2004b [44] fluvoxamine 279 37.3 35.8 12 LSAS, CGI-S GSAD ? ? X ✓ X 
Fahlen et al., 1995 [45] brofaromine 76 37.82 41.56 12 LSAS Mixed ? ? X ✓ X 
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Feltner et al., 2011 [46] pregabalin**** 329 35.1 39.8 10 LSAS GSAD ? ? X ✓ X 
Furmark et al., 2005 [47] citalopram; 
GR205171 
36 31.6 52.8 6 CGI-S Mixed ? ✓ ? ✓ ? 
Gelernter et al., 1991 [48] alprazolam; 
phenelzine 
65 36.5 63 12 FQ Mixed  ? ✓ ✓ ? ? 
Gergel et al., 1997 [49] paroxetine 187 NR NR 12 LSAS Mixed ? ? X ✓ X 
Gimenez et al., 2014 [50] paroxetine 33 23.0 84.8 8 LSAS Mixed ? ✓ ✓ ✓ ? 
GlaxoSmithKline, 2013 [51] paroxetine 239 35.2 42 12 LSAS; CGI-S Mixed ✓ ✓ ✓ ✓ ✓ 
Heimberg et al., 1998 [52] phenelzine 81 34.9 49.6 12 SPDSC Mixed ? ? ✓ ✓ ? 
Kasper et al., 2005 [53] escitalopram 358 37.5 45.5 12 LSAS GSAD ? ✓ X ✓ X 
Katschnig et al., 1997 [54] moclobemide*** 578 36.4 43 12 LSAS Mixed ? ✓ X ✓ X 
Katzelnick et al., 1995 [55] sertraline 12 42.6 33.3 10 LSAS Mixed ? ? X ✓ X 
Kobak et al., 2002 [21]** fluoxetine 60 39.5 58.0 14 LSAS GSAD ? ? X ✓ X 
Kobak et al., 2005 [56] St. John's Wort 40 37.5 52.5 12 LSAS GSAD ? ? X ✓ X 
Lader et al., 2004 [57] escitalopram****; 
paroxetine 
820 36.9 47.2 24 LSAS; CGI-S GSAD ? ? X ✓ X 
Lepola et al., 2004 [58] paroxetine 370 38.9 50.0 12 CGI-S Mixed ? ? ? ✓ ? 
Liebowitz et al., 1992 [59] atenolol; 
phenelzine 
74 34.3 31.0 8 CGI-S Mixed ? ? ✓ ✓ ? 
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Liebowitz et al., 2002 [60] paroxetine**** 360 37.0 41.4 12 LSAS; CGI-S GSAD ? ? X ✓ X 
Liebowitz et al., 2003 [22]** sertraline 401 35.1 40.5 12 LSAS; CGI-S GSAD ? ? X ✓ X 
Liebowitz et al., 2005a [61] paroxetine; 
venlafaxine ER 
413 36.3 46.5 12 LSAS; CGI-S GSAD ? ? X ✓ X 
Liebowitz et al., 2005b [62] venlafaxine ER 271 35.4 45.0 12 LSAS GSAD ? ? X ✓ X 
Lott et al., 1997 [63] brofaromine 102 36.5 39.2 10 LSAS Mixed ? ? X ✓ X 
Noyes et al., 1997 [64] moclobemide***** 506 38.1 42.7 12 LSAS; CIS-SP Mixed ? ✓ X ✓ X 
Oosterbaan et al., 2001 [65]* moclobemide 67 37 41.5 15 LSAS Mixed ? ✓ ? ✓ ? 
Pande et al., 1999 [66] gabapentin 69 35.6 42.0 14 LSAS Mixed ? ? X ✓ X 
Pande et al., 2004 [23]** pregabalin*** 135 38.4 41.5 10 CGI-S GSAD ? ? X ✓ X 
Pfizer, 2007 [67] paroxetine; 
pregabalin*** 
371 37 38 10 LSAS; CGI-S GSAD ? ? X ✓ X 
Rickels et al., 2004 [68] venlafaxine ER 261 41.5 55.6 12 LSAS; CGI-S GSAD ? ? X ✓ X 
Schneier et al., 1998 [69] moclobemide 77 35.5 44.9 8 LSAS Mixed ? ? ✓ ✓ ? 
Schutters et al., 2010 [70] mirtazapine 60 38.6 56.7 12 LSAS GSAD ? ? ✓ ✓ ? 
Stein et al., 1998 [71] paroxetine 187 NR NR 12 LSAS GSAD ✓ ✓ X ✓ X 
Stein et al., 1999 [72] fluvoxamine 92 39.4 35.9 12 LSAS Mixed ? ? X ✓ X 
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Stein et al., 2002 [73] moclobemide 377 34.4 47.0 12 LSAS Mixed ? ? X ✓ X 
Stein et al., 2005 [74] venlafaxine ER*** 364 36.9 41.7 24 LSAS GSAD ✓ ✓ X ✓ X 
Tauscher et al., 2009 [76] paroxetine 129 NR NR 12 LSAS GSAD ? ? X ✓ X 
TIMCTG, 1997 [77] moclobemide*** 578 36.4 43.0 12 LSAS; CIS-SP Mixed ? ✓ ? ✓ ? 
van Ameringen et al., 2001 [78] sertraline 203 35.7 44.4 20 CGI-S GSAD ? ? X ✓ X 
van Vliet et al., 1992 [79] brofaromine 29 NR NR 12 LSAS Mixed ? ? ✓ ✓ ? 
van Vliet et al., 1994 [80] fluvoxamine 28 35.2 56.67 12 LSAS Mixed ? ? ✓ ✓ ? 
Versiani et al., 1992 [81] moclobemide; 
phenelzine 
78 NR NR 8 CGI-S Mixed ? ? X ✓ X 
Westenberg et al., 2004 [82] fluvoxamine 294 38.0 52.0 12 LSAS; CGI-S GSAD ? ? X ✓ X 
Zhang et al., 2005 [83] levetiracetam 16 37.5 53.0 7 LSAS Mixed ? ? X ✓ X 
*Long	term	follow	up	data	were	reported	in	this	study	or	a	follow	up	study	
**Study	had	quality	of	life	outcomes	reported	
***Study	included	2	doses	of	the	same	medication	
****Study	included	3	doses	of	the	same	medication	
*****Study	included	5	doses	of	the	same	medication	
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Table 2. Effect sizes for pre-post, pre-FU, and QoL 
Category 
 
 
Medication 
Group Medication Study Hedges's g SE 
95% 
CI 
Low 
95% 
CI 
High Z p 
Pre-post Anticonvulsant gabapentin Pande et al., 1999 0.53 0.24 0.05 1.00 2.18 0.03 
  pregabalin (150mg) Pande et al., 2004 0.04 0.21 -0.37 0.46 0.21 0.83 
 
 pregabalin (600 
mg) Pande et al., 2004 
0.34 0.21 -0.06 0.75 1.66 0.10 
  pregabalin (200mg) Pfizer, 2007 0.25 0.16 -0.07 0.57 1.56 0.13 
  pregabalin (400mg) Pfizer, 2007 0.03 0.17 -0.29 0.35 0.16 0.87 
  levetiracetam Zhang et al., 2005 0.39 0.48 -0.55 1.34 0.82 0.41 
Pooled 
anticonvulsant 
 
  
0.21 0.08 0.05 0.38 2.52 0.01 
 Antipsychotics olanzapine Barnett et al., 2002 0.72 0.56 -0.38 1.82 1.29 0.20 
Pooled 
antipsychotics 
 
  
0.72 0.56 -0.38 1.82 1.29 0.20 
 Benzodiazepines clonazepam Davidson et al., 1993 0.97 0.24 0.49 1.44 4.00 0.00 
  alprazolam Gelernter et al., 1991 0.49 0.38 -0.25 1.24 1.30 0.19 
Pooled 
benzodiazepines 
 
  
0.82 0.22 0.40 1.25 3.78 0.00 
 
Beta-blockers atenolol Liebowitz et al., 1992 0.08 0.28 -0.47 0.64 0.30 0.77 
Pooled beta-
blockers 
 
  
0.08 0.28 -0.47 0.64 0.30 0.77 
 Herbal St. John's Wort Kobak et al., 2005 -0.07 0.31 -0.68 0.54 -0.22 0.82 
Pooled herbal    -0.07 0.31 -0.68 0.54 -0.22 0.82 
 MAO-A brofaromine Fahlen et al., 1995 0.70 0.23 0.24 1.16 2.98 0.00 
 
 brofaromine Lott et al., 1997 0.36 0.20 -0.03 0.75 1.81 0.07 
  brofaromine van Vliet et al., 1992 1.02 0.39 0.26 1.78 2.62 0.01 
Pooled MAO-A    0.60 0.17 0.26 0.94 3.44 0.00 
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 MAOI phenelzine Blanco et al., 2010 0.49 0.26 -0.02 0.99 1.90 0.06 
  phenelzine Gelernter et al., 1991 0.33 0.37 -0.40 1.06 0.89 0.37 
  phenelzine Heimberg et al., 1998 1.15 0.29 0.57 1.72 3.91 0.00 
 
 moclobemide 
(300mg) Katschnig et al., 1997 
0.22 0.10 0.02 0.42 2.15 0.03 
 
 moclobemide 
(600mg) Katschnig et al., 1997 
0.28 0.10 0.08 0.48 2.73 0.01 
  phenelzine Liebowitz et al., 1992 0.86 0.29 0.30 1.43 2.99 0.00 
 
 moclobemide 
(150mg) Noyes et al., 1997 
0.17 0.15 -0.13 0.47 1.10 0.27 
 
 moclobemide 
(300mg) Noyes et al., 1997 
0.12 0.15 -0.18 0.42 0.78 0.44 
 
 moclobemide 
(600mg) Noyes et al., 1997 
0.13 0.15 -0.17 0.43 0.84 0.40 
 
 moclobemide 
(75mg) Noyes et al., 1997 
0.01 0.15 -0.29 0.31 0.08 0.93 
 
 moclobemide 
(900mg) Noyes et al., 1997 
0.19 0.15 -0.12 0.49 1.21 0.23 
  moclobemide Oosterbaan et al., 2001 -0.25 0.30 -0.85 0.34 -0.83 0.40 
  moclobemide Schneier et al., 1998 0.20 0.23 -0.25 0.65 0.89 0.37 
  moclobemide Stein et al., 2002 0.26 0.10 0.06 0.47 2.56 0.01 
 
 moclobemide 
(300mg) TIMCTG, 1997 
0.37 0.10 0.17 0.57 3.64 0.00 
 
 moclobemide 
(600mg) TIMCTG, 1997 
0.19 0.10 -0.01 0.39 1.84 0.07 
  moclobemide Versiani et al., 1992 1.22 0.30 0.64 1.81 4.10 0.00 
  phenelzine Versiani et al., 1992 2.16 0.35 1.48 2.84 6.25 0.00 
Pooled MAOI    0.36 0.08 0.21 0.51 4.74 0.00 
 NaSSA mirtazapine Schutters et al., 2010 0.13 0.26 -0.37 0.63 0.51 0.61 
Pooled NaSSA    0.13 0.26 -0.37 0.63 0.51 0.61 
 NK1 GR205171 Furmark et al., 2005 0.46 0.40 -0.33 1.24 1.14 0.25 
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Pooled NK1    0.46 0.40 -0.33 1.24 1.14 0.25 
 SNRI venlafaxine ER Allgulander et al., 2004 0.62 0.13 0.37 0.87 4.92 0.00 
  venlafaxine ER Liebowitz et al., 2005a 0.40 0.12 0.16 0.63 3.29 0.00 
  venlafaxine ER Liebowitz et al., 2005b 0.48 0.12 0.23 0.72 3.87 0.00 
  venlafaxine ER Rickels et al., 2004 0.37 0.12 0.12 0.61 2.94 0.00 
 
 venlafaxine ER 
(150mg) Stein et al., 2005 
0.42 0.13 0.17 0.68 3.29 0.00 
 
 venlafaxine ER 
(75mg) Stein et al., 2005 
0.42 0.13 0.17 0.68 3.29 0.00 
Pooled SNRI    0.45 0.05 0.35 0.55 8.82 0.00 
 
SSRI paroxetine Allgulander et al., 1999 0.84 0.22 0.42 1.27 3.90 0.00 
 
 paroxetine Allgulander et al., 2004 0.59 0.13 0.34 0.83 4.64 0.00 
 
 fluvoxamine Asakura et al., 2007 0.30 0.13 0.05 0.56 2.33 0.02 
 
 paroxetine Baldwin et al., 1999 0.50 0.12 0.26 0.73 4.18 0.00 
 
 sertraline Blomhoff et al., 2001 0.27 0.15 -0.02 0.56 1.83 0.07 
 
 fluoxetine Clark et al., 2003 0.11 0.31 -0.50 0.72 0.35 0.72 
 
 fluoxetine Davidson et al., 2004a 0.56 0.19 0.19 0.92 2.96 0.00 
  fluvoxamine Davidson et al., 2004b 0.51	 0.13	 0.26	 0.77	 3.98	 0.00	
 
 citalopram Furmark et al., 2005 0.32 0.40 -0.46 1.10 0.81 0.42 
  paroxetine Gergel et al., 1997 0.62 0.15 0.33 0.91 4.17 0.00 
  paroxetine Gimenez et al., 2014 1.15 0.37 0.43 1.87 3.12 0.00 
  paroxetine GSK, 2013 0.88 0.28 0.33 1.43 3.12 0.00 
 
 escitalopram Kasper et al., 2005 0.25 0.11 0.04 0.46 2.34 0.02 
 
 sertraline Katzelnick et al., 1995 0.80 0.56 -0.30 1.89 1.43 0.15 
 
 fluoxetine Kobak et al., 2002 -0.03 0.25 -0.53 0.47 -0.11 0.91 
 
 escitalopram 
(10mg) Lader et al., 2004 
0.25 0.11 0.03 0.47 2.27 0.02 
 
 escitalopram 
(20mg) Lader et al., 2004 
0.37 0.11 0.15 0.59 3.29 0.00 
 
 escitalopram (5mg) Lader et al., 2004 0.28 0.11 0.07 0.50 2.58 0.01 
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 paroxetine Lader et al., 2004 0.32 0.11 0.11 0.54 2.94 0.00 
 
 paroxetine Lepola et al., 2004 0.64 0.11 0.43 0.85 6.02 0.00 
 
 paroxetine (20 mg) Liebowitz et al., 2002 0.47 0.15 0.18 0.77 3.14 0.00 
 
 paroxetine (40 mg) Liebowitz et al., 2002 0.36 0.15 0.06 0.65 2.38 0.02 
 
 paroxetine (60 mg) Liebowitz et al., 2002 0.33 0.15 0.04 0.62 2.20 0.03 
 
 sertraline Liebowitz et al., 2003 0.33 0.10 0.14 0.53 3.31 0.00 
 
 paroxetine Liebowitz et al., 2005a 0.40 0.12 0.16 0.64 3.29 0.00 
  paroxetine Pfizer, 2007 0.44 0.16 0.12 0.76 2.73 0.01 
  paroxetine Stein et al., 1998 0.63 0.15 0.33 0.93 4.18 0.00 
 
 fluvoxamine Stein et al., 1999 0.67 0.22 0.24 1.10 3.04 0.00 
  paroxetine Tauscher et al., 2009 1.37 0.26 0.86 1.88 5.29 0.00 
 
 
sertraline 
van Ameringen et al., 
2001 
0.38 0.15 0.09 0.68 2.58 0.01 
  fluvoxamine van Vliet et al., 1994 0.75 0.38 0.00 1.50 1.95 0.05 
 
 fluvoxamine Westenberg et al., 2004 0.27 0.12 0.04 0.50 2.31 0.02 
Pooled SSRI 
 
 
  
0.44 0.04 0.37 0.51 12.17 0.00 
Pooled Overall    0.41 0.03 0.36 0.46 16.34 0.00 
 
Pre-follow up 
 
clonazepam Davidson et al., 1993 0.50 0.27 -0.04 1.04 1.81 0.07 
  moclobemide Oosterbaan et al., 2001 0.02 0.30 -0.57 0.61 0.06 0.95 
Pooled Overall    0.27 0.24 -0.20 0.74 1.14 0.25 
Quality of Life  fluoxetine Kobak et al., 2002 0.20 0.26 -0.30 0.71 0.80 0.42 
  sertraline Liebowitz et al., 2003 0.39 0.01 0.20 0.58 3.94 0.00 
  pregabalin (150mg) Pande et al., 2004 0.07 0.21 -0.34 0.49 0.35 0.72 
  pregabalin (600mg) Pande et al., 2004 0.09 0.21 -0.31 0.50 0.46 0.65 
Pooled Overall    0.28 0.08 0.13 0.44 3.52 0.00 
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Figure 1 
 
	 	Potentially relevant abstracts identified 
and screened for retrieval (n = 2208) 
Articles selected for further 
screening (n = 119) 
	
Abstracts excluded due to lack of 
relevance to the study (n=2099) 
Articles excluded (n = 67) for the following 
reasons:  
• No active control group (n = 22)  
• No DSM diagnosis of SAD (n = 11)  
• Necessary measures not included (n = 
12)  
• Treatment responders only (n = 6)  
• Augmentation studies (n = 5)  
• Insufficient data (n = 4)  
• < 2 treatment doses (n = 2)  
• No pharmacotherapy (n = 5)  
 
Studies included in the meta-
analysis (n = 52) 
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